-
A5422: CH505 TF chTrimer Vaccination in Adults Living with HIV-1 on Suppressive ART
This study is looking to see if an investigational anti-HIV vaccine (stabilized CH505 TF chTrimer) is safe and well-tolerated in…
Active, Not Recruiting
Treatment Experienced
Participants will be on study for about 2 years (100 weeks).
-
People with HIV can have an increase in inflammation in their body organs even after taking anti-HIV medicines (ART, or…
Closed to accrual
Treatment Experienced
24 weeks
-
A5385: An Observational Post-Intervention Cohort Destination Protocol
This study is a two-step, non-interventional extension study for individuals participating in another interventional HIV cure trial (parent study) that…
Open and enrolling
Treatment Experienced
-
Current antiretroviral therapy (ART) does not cure HIV. ART just holds the virus in check so it cannot multiply and…
Open and enrolling
Treatment Experienced
Up to approximately 110 weeks depending on the time spent in Part 2 of the study.
-
Transgender women (TW) are the fastest-growing group of people with HIV. Historically, TW have had few opportunities to participate in…
Open and enrolling
Treatment Experienced
Participants will complete about seven (7) visits over the course of 1 year.
-
AHRC (pronounced “ARC”) is a study of differences and changes over time in HIV reservoirs (groups of HIV-infected cells that…
Open and enrolling
HIV Cure, Treatment Experienced
Participants will be expected to stay in the study for about 7 years.
